Improved Clinical Outcomes With Early Anti-Tumour Necrosis Factor Alpha Therapy in Children With Newly Diagnosed Crohn’s Disease: Real-world Data from the International Prospective PIBD-SETQuality Inception Cohort Study
Authors:
- Renz C W KlombergRKRenz C W Klomberg
- Dimitris RizopoulosDRDimitris Rizopoulos
- Mohammed CharroutMCMohammed Charrout
- Nicholas M CroftNCNicholas M Croft
- Lissy de RidderLRLissy de Ridder
- PIBD-SETQuality collaborative groupPGPIBD-SETQuality collaborative group
Open Access
- 27 November 2023
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 18 (5) , 738-750
Abstract
Background and Aims: Treatment guidelines for paediatric Crohn’s disease [CD] suggest early use of anti-tumour necrosis factor alpha [anti-TNFα] in high-risk individuals. The aim is to evaluate the effect of early anti-TNF in a real-world cohort. Methods: Children with newly diagnosed CD were prospectively recruited at 28 participating sites of the international observational PIBD-SETQuality study. Outcomes were compared at 3 months, 1 and 2 years between patients receiving early anti-TNF [<90 days after diagnosis] and those not receiving early anti-TNF. Outcomes included sustained steroid-free remission [SSFR] without treatment intensification [specified as SSFR*] and sustained steroid-free mild/inactive disease without treatment intensification [specified as SSFMI*]. Penalised logistic regression model-based standardisation was applied to estimate the relative risks [RR] of early therapy on outcomes. RRs were estimated for high-risk and low-risk patients, based on presence of predictors of poor outcome [POPOs] and disease activity at diagnosis. Results: In total, 331 children (median age 13.9 years [IQR 12.2–15.3]) were enrolled, with 135 [41%] receiving early anti-TNF. At 1 year, patients on early anti-TNF had higher rates of SSFR* [30% vs 14%, p <0.001] and SSFMI* [69% vs 33%, p <0.001], with RRs of 2.95 [95% CI 1.63-5.36] and 4.67 [95% CI 2.46-8.87], respectively. At 1 year, the RRs for SSFMI* were higher, and statistically significant in high-risk patients, i.e. those with moderate/severe disease compared with mild/inactive disease at diagnosis (5.50 [95% CI 2.51-12.05] vs 2.91 [95% CI 0.92-9.11]), and those with any POPO compared with no POPO (5.05 [95% CI 2.45-10.43] vs 3.41 [95% CI 0.54-21.7]). Conclusion: In this cohort of children with newly-diagnosed CD, early anti-TNF demonstrated superior effectiveness in high-risk patients.Keywords
Funding Information
- European Union’s Horizon (668023)
This publication has 34 references indexed in Scilit:
- Prospective Evaluation of the Achievement of Mucosal Healing with Anti-TNF-α Therapy in a Paediatric Crohn’s Disease CohortJournal of Crohn's and Colitis, 2015
- Early anti-TNF treatment in pediatric Crohn’s disease. Predictors of clinical outcome in a population-based cohort of newly diagnosed patientsScandinavian Journal of Gastroenterology, 2014
- ESPGHAN Revised Porto Criteria for the Diagnosis of Inflammatory Bowel Disease in Children and AdolescentsJournal of Pediatric Gastroenterology and Nutrition, 2014
- Increased Effectiveness of Early Therapy With Anti-Tumor Necrosis Factor-α vs an Immunomodulator in Children With Crohn's DiseaseGastroenterology, 2014
- Mathematical weighting of the pediatric Crohnʼs disease activity index (PCDAI) and comparison with its other short versionsInflammatory Bowel Diseases, 2012
- Pediatric modification of the Montreal classification for inflammatory bowel diseaseInflammatory Bowel Diseases, 2011
- Infliximab therapy in children with Crohn’s disease: a one‐year evaluation of efficacy comparing ‘top‐down’ and ‘step‐up’ strategiesActa Paediatrica, 2011
- Linear Growth Improves during Infliximab Therapy in Children with Chronically Active Severe Crohnʼs DiseaseInflammatory Bowel Diseases, 2007
- Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CDGastrointestinal Endoscopy, 2004
- Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn’s diseaseDigestive and Liver Disease, 2004